By being a dual neurokinin-1 and neurokinin-3 receptor antagonist that targets the underlying neuroendocrine pathways responsible for vasomotor symptoms (VMS) such as hot flashes and night sweats, Elinzanetant significantly reduces both the frequency and severity of hot flashes and night sweats in menopausal women. Thanks to its novel mechanism of action, it provides rapid symptom relief compared to traditional hormonal therapies, which leads to meaningful improvements in sleep quality and overall menopause-related quality of life. This is confirmed by multiple randomized controlled trials and meta-analyses. Clinical studies show that Elinzanetant's safety profile is strong, with adverse events occurring at rates similar to placebo and no evidence of serious side effects or liver toxicity making it a great alternative for women who cannot or prefer not to use hormone therapy with Rapid onset of action and minimal side effects to help reduce the overall burden of menopausal symptoms and improve daily functioning. Thank you Dr. Seyed Hassan Fakher MD Preventive Health & Sports Medicine https://www.linkedin.com/in/hassan-fakher-md-322615244/ https://www.invigormedical.com/contributor/dr-seyed-hassan-fakher-md/ Dr.fakher@invigormedical.com Invigor Medical
Neuroscientist | Scientific Consultant in Physics & Theoretical Biology | Author & Co-founder at VMeDx
Answered 5 months ago
Good Day, In which possible ways can elinzanetant be used to improve patient care? Elinzanetant could be a real game changer for women suffering from hot flashes, who either cannot or refuse to use hormone therapy. The fact that it can reduce hot flashes by nearly three-quarters, while having a good safety record over an entire year, is very encouraging. It opens the door to really effective options for women without the risks that hormone treatments sometimes carry. That would be a great step forward in managing menopause symptoms and making many more women feel comfortable and in control during this phase of their lives. If you decide to use this quote, I'd love to stay connected! Feel free to reach me at gregorygasic@vmedx.com and outreach@vmedx.com.
A medication such as elinzanetant would transform women who are not able to or are opposed to the hormone therapy. It addresses symptoms directly by targeting the neurokinin pathway that leads to hot flashes. It thus does not expose patients to estrogen, which is the biggest fear of people with a history of breast cancer, miscarriages or clotting. Practically, this implies fewer women will be presented with a decision between suffering from the vasomotor symptoms and exposure to the hormone risks. I am excited to hear that the data from the trial report show good effectiveness, i.e., a reduction of hot flashes by almost 75% and a favourable safety profile. Should these findings be successful in the broader context, elinzanetant would be promoted to first-line use in many patients, and this would increase their options compared to lifestyle modification or off-label agents, which in most cases may have limited effectiveness. Ultimately, it may help women maintain the quality of life during midlife transitions with fewer trade-offs.